Tag: Therapy
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications ...

Lees verder
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Tr

Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Tr

AACHEN, Germany, and MELBOURNE, Australia, Sept. 10, 2019 /PRNewswire/ -- Grünenthal, a global leader in pain management, and Mesoblast Limited , a world leader in allogeneic ...

Lees verder
ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia

ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia

MELBOURNE, Australia, July 5, 2019 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce the official launch of Gene Therapy ...

Lees verder
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 3, 2019 /PRNewswire/ -- -- ...

Lees verder
Pregnancy And Reproductive History May Impact Dementia Risk Plus, The Move To Re-Think The Impact Of Hormone Therapy On Cognition

Pregnancy And Reproductive History May Impact Dementia Risk Plus, The Move To Re-Think The Impact Of Hormone Therapy On Cognition

Plus, Sex-Based Approaches May Improve Diagnostic Accuracy in Alzheimer's CHICAGO, July 23, 2018 /PRNewswire/ -- Research reported at the Alzheimer's Association International ...

Lees verder
Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcera

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcera

OSAKA, Japan, June 3, 2018 /PRNewswire/ -- Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts ...

Lees verder
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in

Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in

OSAKA, Japan, February 16, 2018 /PRNewswire/ -- New clinical study also provides data for Entyvio(R) in inducing complete mucosal healing and endoscopic remission, ...

Lees verder
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

DARMSTADT, Germany and NEW YORK, December 21, 2017 /PRNewswire/ -- - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer  - Renal ...

Lees verder
4C Medical's Novel Mitral Regurgitation Therapy to be Presented at TCT 2017 Shark Tank Innovation Competition

4C Medical's Novel Mitral Regurgitation Therapy to be Presented at TCT 2017 Shark Tank Innovation Competition

BROOKLYN PARK, Minnesota, Oct. 24, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, ...

Lees verder
4C Medical's Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit

4C Medical's Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit

BROOKLYN PARK, Minnesota, Aug. 3, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive therapies for structural heart disease, ...

Lees verder
BizPress.nl